NCT07015905: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 2 years, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT07015905 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 25, 2025 |
| Completion date | Feb. 20, 2027 |
| Required reporting date | Feb. 20, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |